All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
66 results for "Cancer" and "Head and Neck Cancers"
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Protocol No
NRG-GU012-SAMURAI
Sub Category
A Dose Escalation and Dose Expansion Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients with Soft Tissue Sarcoma - CEP-2
To estimate the maximum tolerated dose (MTD) of NOX66 in combination with doxorubicin. To characterize the safety and tolerability of NOX66 alone and in combination with doxorubicin.
Protocol No
NOXOPHARM-NOX66-004
Sub Category
A Phase 1/2 dose escalation and dose expansion study of BA3011 alone and in combination with Nivolumab in adult and adolescent patients 12 years and older with advanced solid tumors
The purpose of this study is to learn about the safety and effectiveness of an experimental drug called Mecbotamab Vedotin (BA3011) on a variety of cancers that have tested positive for the AXL protein.
Protocol No
BIOATLA-BA3011-001
Sub Category
Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 MG/M2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 MG/M2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Comparing high-dose cisplatin every three weeks to low-dose cisplatin weekly when combined with radiation for patients with advanced head and neck cancer
Protocol No
NRG-HN009
Sub Category
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T Cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
ADP-A2M4 SPEAR T Cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Protocol No
ADP-0044-002-SPEARHEAD-1
Sub Category
Phase 1/1b Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors
To assess the safety and tolerability of ociperlimab in combination with tislelizumab in
patients with advanced solid tumors. Then to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of ociperlimab in combination with tislelizumab, and determine the recommended Phase 2 dose (RP2D) of ociperlimab in combination with
tislelizumab.
patients with advanced solid tumors. Then to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of ociperlimab in combination with tislelizumab, and determine the recommended Phase 2 dose (RP2D) of ociperlimab in combination with
tislelizumab.
Protocol No
BEIGENE-BGB-900-105
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Testing the addition of radiation therapy to the usual immune therapy treatment (atezolizumab) for patients with extensive stage small cell lung cancer
Protocol No
NRG-LU007
Sub Category
Recognition of Circulating Tumor DNA in Sarcoma
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
Protocol No
IIT-BEDI-CTDNA
Sub Category
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
Olanzapine vs Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Protocol No
ALLIANCE-A222004-ANOREXIA
A Phase 1b/2 Study of AVB-S6-500 in Combination with Cabozantinib, AVB-S6-500 in Combination with Cabozantinib and Nivolumab, and AVB-S6-500 Monotherapy in Patients with Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Protocol No
ARAVIVE-AVB500-RCC-003
Sub Category
A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred with High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
Erdafitinib vs Investigator Choice of Intravesical Chemo for NMIBC Pts Who Recurred After BCG
Protocol No
JANSSEN-42756493BLC2003-THOR-2
Sub Category
High Dose Re-Irradiation Utilizing Advanced Defromable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Phase III Trial of Immunotherapy-Based Combination Therapy with or without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (Probe Trial)
Immunotherapy-Based Drug Combo w wo Surgery to Remove Kidney in Mets Kidney Cancer
Protocol No
SWOG-S1931-PROBE-TRIAL
Sub Category
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (Dragon)
Evaluate the safety and tolerability of single-agent SRK-181 and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and evaluate dose-limiting toxicities (DLTs) of single-agent SRK-181.
Protocol No
SCHOLARROCK-SRK-181-001
A Phase II Study of Cabozantinib and Temozolomide in Patients with Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
Protocol No
NU-19S01
Sub Category
Phase 1/2 Study Of REGN4336 (A PSMAXCD3 Bispecific Antibody) Administered Alone Or In Combination With Cemiplimab In Patients With Metastatic Castration-Resistant Prostate Cancer
To assess the safety, tolerability, and PK and to determine RP2DR of REGN4336
separately as monotherapy or in combination with cemiplimab.
separately as monotherapy or in combination with cemiplimab.
Protocol No
REGENERON-R4336-ONC-20104
A Phase I Study of Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers (HART-HN)
Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers (HART-HN)
Protocol No
IIT-AWAN-HART-HN
Sub Category
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST chemo-IO
Testing the addition of a type of drug called immunotherapy to the usual chemotherapy treatment for non-small cell lung cancer
Protocol No
ALLIANCE-ALCHEMIST-A081801
Sub Category
A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
The purpose of this study is to test the levels of the investigational medicine (not approved by the FDA), named DF6002, in your blood, the safety of DF6002, and how people with some types of solid tumor cancers respond to the investigational medicine.
Protocol No
DRAGONFLY-DF6002-001
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors
Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
Protocol No
TOLERO-TP-1287-101